Orladeyo Approved in Japan to Prevent Swelling Attacks Due to HAE

Orladeyo Approved in Japan to Prevent Swelling Attacks Due to HAE

283989

Orladeyo Approved in Japan to Prevent Swelling Attacks Due to HAE

Japan’s Ministry of Health, Labor and Welfare (MHLW) has approved oral Orladeyo (berotralstat), at a daily dose of 150 mg, to prevent hereditary angioedema (HAE) attacks in individuals ages 12 and up. According to the therapy’s developer, BioCryst Pharmaceuticals, Orladeyo is the first prophylactic, or preventive, HAE medication approved in Japan. It will be marketed there by Biocryst’s partner, Torii Pharmaceutical, which plans to launch the medication after pricing negotiations with the Japanese National Health Insurance System (NHI)…

You must be logged in to read/download the full post.